

ENDO PHARMACEUTICALS HOLDINGS INC
Form SC 13D/A
November 21, 2007

**OMB
APPROVAL**
OMB Number:
Expires: February
28, 2009
Estimated
average burden
hours per
response 14.5

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)***

ENDO Pharmaceuticals Holdings Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class Securities)

29264F205

**D. E. Shaw & Co., L.P.
Attn: Compliance Department
120 West Forty-Fifth Street
Floor 39, Tower 45
New York, NY 10036
212-478-0000**

**(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communication)**

Copies to:

**Christopher Boies, Esq.
Boies, Schiller & Flexner LLP
575 Lexington Avenue**

New York, NY 10022

November 16, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.

29264F205

1 Name of Reporting Person.
I.R.S. IDENTIFICATION

D. E. Shaw Composite Portfolios, L.L.C.
FEIN 13-4152438

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3 SEC Use Only

4 Source of Funds (See Instructions)

WC

5 Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6 Citizenship or Place of Organization

Delaware

7

Sole Voting Power

Number of
Shares **8**

-0-

Shared Voting Power

Beneficially

Owned by

7,654,219

Each **9**

Sole Dispositive Power

Reporting

Person With

-0-

10

Shared Dispositive Power

7,654,219

11 Aggregate Amount Beneficially Owned by Each Reporting Person

7,654,219

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13 Percent of Class Represented by Amount in Row (11)

5.7%

14 Type of Reporting Person (See Instructions)

OO

CUSIP No.

29264F205

- 1** Name of Reporting Person.
I.R.S. IDENTIFICATION

D. E. Shaw Valence Portfolios, L.L.C.
FEIN 13-4046559
- 2** Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
- 3** SEC Use Only
- 4** Source of Funds (See Instructions)

WC
- 5** Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
- 6** Citizenship or Place of Organization

Delaware
- 7** Sole Voting Power
- Number of Shares Beneficially Owned by Each Reporting Person With **8** -0- Shared Voting Power
- 9** 3,599,041 Sole Dispositive Power
- 10** -0- Shared Dispositive Power
- 3,599,041
- 11** Aggregate Amount Beneficially Owned by Each Reporting Person 1
3,599,041
- 12** Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
- 13** Percent of Class Represented by Amount in Row (11)
2.7%
- 14** Type of Reporting Person (See Instructions)

OO

¹ The 3,599,041 Common Shares set forth above include (a) 3,574,041 Common Shares owned by Valence, and (b) 25,000 Common Shares which Valence has the right to acquire through the exercise of listed call options.

CUSIP No.

29264F205

- 1** Name of Reporting Person.
I.R.S. IDENTIFICATION
- D. E. Shaw & Co., L.L.C.
FEIN 13-3799946
- 2** Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
- 3** SEC Use Only
- 4** Source of Funds (See Instructions)
- AF
- 5** Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
- 6** Citizenship or Place of Organization
- Delaware
- | | | |
|---|-----------|-------------------------------------|
| | 7 | Sole Voting Power |
| Number of Shares Beneficially Owned by Each Reporting Person With | 8 | -0- Shared Voting Power |
| | 9 | 7,654,219 Sole Dispositive Power |
| | 10 | -0- Shared Dispositive Power |
| | | 7,654,219 |
- 11** Aggregate Amount Beneficially Owned by Each Reporting Person
- 7,654,219
- 12** Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
- 13** Percent of Class Represented by Amount in Row (11)
- 5.7%
- 14** Type of Reporting Person (See Instructions)
- OO

CUSIP No.

29264F205

1 Name of Reporting Person.
I.R.S. IDENTIFICATION

D. E. Shaw & Co., L.P.
FEIN 13-3695715

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)

3 SEC Use Only

4 Source of Funds (See Instructions)

AF

5 Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6 Citizenship or Place of Organization

Delaware

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With

8 -0- Shared Voting Power

9 11,276,856 Sole Dispositive Power

10 -0- Shared Dispositive Power

11,286,836

11 Aggregate Amount Beneficially Owned by Each Reporting Person

11,286,836

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13 Percent of Class Represented by Amount in Row (11)

8.4%

14 Type of Reporting Person (See Instructions)

IN, PN

CUSIP No.

29264F205

- 1** Name of Reporting Person.
I.R.S. IDENTIFICATION
- David E. Shaw
- 2** Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
- 3** SEC Use Only
- 4** Source of Funds (See Instructions)
- AF
- 5** Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
- 6** Citizenship or Place of Organization
- Delaware
- | | | |
|---|-----------|--------------------------------------|
| | 7 | Sole Voting Power |
| Number of Shares Beneficially Owned by Each Reporting Person With | 8 | -0- Shared Voting Power |
| | 9 | 11,276,856 Sole Dispositive Power |
| | 10 | -0- Shared Dispositive Power |
| | | 11,286,836 |
- 11** Aggregate Amount Beneficially Owned by Each Reporting Person
- 11,286,836
- 12** Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
- 13** Percent of Class Represented by Amount in Row (11)
- 8.4%
- 14** Type of Reporting Person (See Instructions)
- IN

AMENDMENT NO. 2 TO SCHEDULE 13D

This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 27, 2007, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on October 12, 2007 (as amended, the "Schedule 13D"). Capitalized terms used herein which are not defined herein have the meanings given to such terms in the Schedule 13D. Except as otherwise provided herein, all Items of the Schedule 13D remain unchanged.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby supplemented as follows:

In acquiring 1,028,106 additional Common Shares owned by Composite since October 12, 2007, Composite expended approximately \$28,658,990 (excluding commissions) of its working capital. In acquiring 524,212 additional Common Shares owned by Valence since October 12, 2007, Valence expended approximately \$14,430,375 (excluding commissions) of its working capital.

Item 5. Interest in Securities of the Issuer

Item 5 of the 13D is hereby supplemented as follows:

(a), (b) Based upon the Issuer's Form 10-Q, filed with the Securities and Exchange Commission on November 2, 2007, there were 134,112,148 Common Shares issued and outstanding as of October 26, 2007. The 7,654,219 Common Shares beneficially owned by Composite (the "Composite Shares") represent approximately 5.7% of the Common Shares issued and outstanding. The 3,599,041 Common Shares beneficially owned by Valence (the "Valence Shares") represent approximately 2.7% of the Common Shares issued and outstanding.² As of November 20, 2007, Synoptic does not hold a long position in the Common Shares. The 7,654,219 Common Shares beneficially owned by DESCO LLC represent approximately 5.7% of the Common Shares issued and outstanding. The 11,286,836 Common Shares beneficially owned by DESCO LP (the "Subject Shares") represent approximately 8.4% of the Common Shares issued and outstanding. The Subject Shares are comprised of (i) the Composite Shares, (ii) the Valence Shares, and (iii) 33,576 Common Shares under the management of DESIM LLC (the "DESIM Shares").

Composite has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) the Composite Shares. Valence has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) the Valence Shares. DESIM LLC has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) 23,596 of the DESIM Shares, and the shared power to dispose or direct the disposition of (but not the power to vote or to direct the vote of) 9,980 of the DESIM Shares. Composite disclaims beneficial ownership of the Common Shares beneficially owned by Valence and DESIM LLC; Valence disclaims beneficial ownership of the Common Shares beneficially owned by Composite

and DESIM LLC; Synoptic disclaims beneficial ownership of the Common Shares beneficially owned by Composite, Valence, and DESIM LLC; and DESIM LLC disclaims beneficial ownership of the Common Shares beneficially owned by Composite and Valence.

DESCO LP, as managing member and investment adviser of Valence, investment adviser of Composite, and managing member of DESIM LLC, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Composite Shares and the Valence Shares, and the shared power to vote or direct the vote of (and the power to dispose or direct the disposition of) 23,596 of the DESIM Shares, and the shared power to dispose or direct the disposition of (but not the power to vote or to direct the vote of) 9,980 of the DESIM Shares. DESCO LLC, as Composite's managing member, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Composite Shares. As managing member of DESCO LLC, DESCO II, Inc. may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the Composite Shares. As general partner of DESCO LP, DESCO, Inc. may be deemed to have the shared power to vote or to direct the vote of (and the shared power to dispose or direct the disposition of) the Composite Shares and the Valence Shares, and the shared power to vote or direct the vote of (and the power to dispose or direct the disposition of) 23,596 of the DESIM Shares, and the shared power to dispose or direct the disposition of (but not the power to vote or to direct the vote of) 9,980 of the DESIM Shares. None of DESCO LP, DESCO LLC, DESCO, Inc., or DESCO II, Inc., owns any Common Shares directly, and each such entity disclaims beneficial ownership of the Subject Shares.

David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of DESCO Inc., which is the general partner of DESCO LP, which in turn is the managing member and investment adviser of Valence, the investment adviser of Composite, and the managing member of DESIM, and by virtue of David E. Shaw's position as President and sole shareholder of DESCO II, Inc., which is the managing member of DESCO LLC, which in turn is the managing member of Composite, David E. Shaw may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Composite Shares and the Valence Shares, and the shared power to vote or direct the vote of (and the power to dispose or direct the disposition of), 23,596 of the DESIM Shares, and the shared power to dispose or direct the disposition of (but not the power to vote or to direct the vote of) 9,980 of the DESIM Shares. David E. Shaw disclaims beneficial ownership of the Subject Shares.

As of the date hereof, neither any Reporting Person nor, to the best knowledge of any Reporting Person, any of the persons set forth in Item 2 owns any Common Shares other than those set forth in this Item 5.

(c) The trading dates, number of Common Shares purchased or sold, and the price per share for all transactions by the Reporting Persons in the Common Shares within the last 60 days through November 20, 2007, which were all

brokered transactions, are set forth below:

² The 3,599,041 Common Shares set forth above include (a) 3,574,041 Common Shares owned by Valence, and (b) 25,000 Common Shares which Valence has the right to acquire through the exercise of listed call options.

| Name | Date | Price per Share | Number of Shares Purchased/(Sold) |
|-------------|-------------|------------------------|--|
| Composite | 10/12/2007 | \$27.79 | 500 |
| Composite | 10/12/2007 | \$27.80 | 11314 |
| Composite | 10/12/2007 | \$28.00 | 80000 |
| Synoptic | 10/12/2007 | \$27.74 | 300 |
| Synoptic | 10/12/2007 | \$27.94 | 2200 |
| Valence | 10/12/2007 | \$27.96 | 3100 |
| Valence | 10/12/2007 | \$27.97 | 400 |
| Valence | 10/12/2007 | \$27.98 | 400 |
| Valence | 10/12/2007 | \$27.99 | 2500 |
| Valence | 10/12/2007 | \$28.00 | 209200 |
| Valence | 10/12/2007 | \$28.02 | (4951) |
| Valence | 10/12/2007 | \$28.03 | (300) |
| Valence | 10/12/2007 | \$28.04 | (5971) |
| Valence | 10/12/2007 | \$28.05 | (4378) |
| Composite | 10/15/2007 | \$27.77 | 3000 |
| Composite | 10/15/2007 | \$27.78 | 1100 |
| Composite | 10/15/2007 | \$27.79 | 10257 |
| Composite | 10/15/2007 | \$27.80 | 36862 |
| Composite | 10/15/2007 | \$27.81 | 681 |
| Composite | 10/15/2007 | \$27.82 | 2600 |
| Composite | 10/15/2007 | \$27.83 | 11450 |
| Composite | 10/15/2007 | \$27.84 | 7050 |
| Composite | 10/15/2007 | \$27.85 | 7000 |
| Composite | 10/15/2007 | \$27.87 | 1600 |
| Composite | 10/15/2007 | \$27.88 | 2600 |
| Composite | 10/15/2007 | \$27.89 | 3849 |
| Composite | 10/15/2007 | \$27.90 | 5751 |
| Composite | 10/15/2007 | \$27.91 | 6200 |
| Synoptic | 10/15/2007 | \$27.80 | (1000) |
| Synoptic | 10/15/2007 | \$27.82 | 906 |
| Composite | 10/16/2007 | \$27.70 | 3222 |
| Composite | 10/16/2007 | \$27.71 | 1778 |
| Composite | 10/16/2007 | \$27.72 | 1700 |
| Composite | 10/16/2007 | \$27.73 | 3700 |
| Composite | 10/16/2007 | \$27.74 | 3000 |
| Composite | 10/16/2007 | \$27.75 | 4650 |
| Composite | 10/16/2007 | \$27.76 | 1000 |
| Composite | 10/16/2007 | \$27.77 | 5859 |
| Composite | 10/16/2007 | \$27.78 | 5341 |
| Composite | 10/16/2007 | \$27.79 | 6600 |
| Composite | 10/16/2007 | \$27.80 | 4300 |
| Composite | 10/16/2007 | \$27.84 | 1200 |
| Composite | 10/16/2007 | \$27.85 | 7650 |
| Synoptic | 10/16/2007 | \$27.80 | 100 |
| Synoptic | 10/16/2007 | \$27.80 | (500) |
| Synoptic | 10/16/2007 | \$27.84 | 100 |
| Synoptic | 10/17/2007 | \$27.87 | 1200 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|------------|---------|-------|
| Synoptic | 10/17/2007 | \$27.89 | (200) |
| Synoptic | 10/17/2007 | \$27.90 | 100 |
| Synoptic | 10/17/2007 | \$27.90 | (34) |
| Synoptic | 10/17/2007 | \$27.91 | 76 |
| Synoptic | 10/18/2007 | \$27.98 | (1) |
| DESIM LLC | 10/19/2007 | \$27.97 | 3000 |
| Synoptic | 10/19/2007 | \$27.86 | (300) |
| Synoptic | 10/19/2007 | \$27.94 | 104 |
| Synoptic | 10/19/2007 | \$27.95 | 2 |
| Valence | 10/19/2007 | \$35.00 | 3400 |
| Composite | 10/22/2007 | \$27.43 | 10044 |
| Composite | 10/22/2007 | \$27.70 | 10856 |
| Composite | 10/22/2007 | \$27.75 | 5096 |
| Composite | 10/22/2007 | \$27.78 | 27200 |
| Composite | 10/22/2007 | \$27.80 | 46804 |
| Synoptic | 10/22/2007 | \$27.70 | 1131 |
| Synoptic | 10/22/2007 | \$27.83 | (100) |
| Synoptic | 10/22/2007 | \$27.88 | (200) |
| Composite | 10/23/2007 | \$27.74 | 28000 |
| Synoptic | 10/23/2007 | \$27.72 | (10) |
| Synoptic | 10/23/2007 | \$27.79 | 200 |
| Synoptic | 10/23/2007 | \$27.80 | 200 |
| Synoptic | 10/24/2007 | \$27.84 | (100) |
| Synoptic | 10/24/2007 | \$27.88 | (100) |
| Synoptic | 10/24/2007 | \$27.89 | (200) |
| Synoptic | 10/24/2007 | \$27.90 | (100) |
| Synoptic | 10/24/2007 | \$27.92 | (200) |
| Synoptic | 10/24/2007 | \$27.93 | (200) |
| Synoptic | 10/24/2007 | \$27.95 | 500 |
| Synoptic | 10/24/2007 | \$27.95 | (100) |
| Synoptic | 10/24/2007 | \$27.99 | 193 |
| Synoptic | 10/24/2007 | \$28.19 | (300) |
| Synoptic | 10/24/2007 | \$28.20 | (100) |
| Composite | 10/25/2007 | \$27.68 | 100 |
| Composite | 10/25/2007 | \$27.70 | 3500 |
| Composite | 10/25/2007 | \$27.73 | 2600 |
| Composite | 10/25/2007 | \$27.74 | 100 |
| Composite | 10/25/2007 | \$27.75 | 1200 |
| Composite | 10/25/2007 | \$27.76 | 100 |
| Composite | 10/25/2007 | \$27.77 | 1300 |
| Composite | 10/25/2007 | \$27.79 | 100 |
| Composite | 10/25/2007 | \$27.80 | 5200 |
| Composite | 10/25/2007 | \$27.83 | 1000 |
| Composite | 10/25/2007 | \$27.84 | 6793 |
| Composite | 10/25/2007 | \$27.85 | 2600 |
| Composite | 10/25/2007 | \$27.86 | 4200 |
| Composite | 10/25/2007 | \$27.87 | 585 |
| Composite | 10/25/2007 | \$27.88 | 200 |
| Composite | 10/25/2007 | \$27.89 | 1100 |
| Composite | 10/25/2007 | \$27.90 | 11471 |
| Composite | 10/25/2007 | \$27.91 | 100 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|------------|---------|--------|
| Composite | 10/25/2007 | \$27.93 | 1800 |
| Composite | 10/25/2007 | \$27.94 | 2063 |
| Composite | 10/25/2007 | \$27.95 | 5159 |
| Composite | 10/25/2007 | \$27.97 | 100 |
| Composite | 10/25/2007 | \$27.98 | 1306 |
| Composite | 10/25/2007 | \$27.99 | 1200 |
| Composite | 10/25/2007 | \$28.00 | 46123 |
| Synoptic | 10/25/2007 | \$27.74 | (800) |
| Synoptic | 10/25/2007 | \$27.77 | (1100) |
| Synoptic | 10/25/2007 | \$27.84 | 40 |
| Synoptic | 10/25/2007 | \$27.85 | 76 |
| Synoptic | 10/25/2007 | \$27.88 | 100 |
| Synoptic | 10/25/2007 | \$27.90 | 43 |
| Synoptic | 10/25/2007 | \$28.01 | 27 |
| Synoptic | 10/25/2007 | \$28.04 | 1000 |
| Synoptic | 10/25/2007 | \$28.04 | (200) |
| Synoptic | 10/25/2007 | \$28.05 | (100) |
| Synoptic | 10/26/2006 | \$28.26 | 1000 |
| Synoptic | 10/26/2006 | \$28.47 | (501) |
| Synoptic | 10/26/2006 | \$28.56 | (62) |
| Synoptic | 10/26/2006 | \$28.57 | 267 |
| Synoptic | 10/26/2006 | \$28.67 | 100 |
| Synoptic | 10/26/2006 | \$28.68 | (100) |
| Synoptic | 10/29/2006 | \$28.58 | (200) |
| Synoptic | 10/29/2006 | \$28.64 | 135 |
| Synoptic | 10/29/2006 | \$28.66 | 102 |
| Synoptic | 10/29/2006 | \$28.81 | (876) |
| Synoptic | 10/30/2007 | \$28.84 | 248 |
| Synoptic | 10/30/2007 | \$29.06 | 1000 |
| Synoptic | 10/30/2007 | \$29.23 | (100) |
| Synoptic | 10/30/2007 | \$29.31 | (5) |
| Synoptic | 10/30/2007 | \$29.39 | 68 |
| Synoptic | 10/30/2007 | \$29.46 | 33 |
| Synoptic | 10/30/2007 | \$29.50 | 38 |
| Synoptic | 10/30/2007 | \$29.58 | (1000) |
| Synoptic | 10/30/2007 | \$29.69 | (100) |
| Synoptic | 10/31/2007 | \$29.33 | 100 |
| Synoptic | 10/31/2007 | \$29.37 | (200) |
| Synoptic | 10/31/2007 | \$29.38 | (34) |
| Synoptic | 10/31/2007 | \$29.46 | (200) |
| Synoptic | 10/31/2007 | \$29.67 | 1149 |
| Synoptic | 11/1/2007 | \$29.18 | (100) |
| Synoptic | 11/1/2007 | \$29.18 | 2 |
| Synoptic | 11/1/2007 | \$29.25 | (9) |
| Synoptic | 11/1/2007 | \$29.34 | 500 |
| Composite | 11/2/2007 | \$27.97 | 2271 |
| Composite | 11/2/2007 | \$27.98 | 700 |
| Composite | 11/2/2007 | \$28.01 | 6580 |
| Composite | 11/2/2007 | \$28.02 | 1000 |
| Composite | 11/2/2007 | \$28.03 | 4064 |
| Composite | 11/2/2007 | \$28.04 | 1900 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|-----------|---------|--------|
| Composite | 11/2/2007 | \$28.05 | 12600 |
| Composite | 11/2/2007 | \$28.06 | 7075 |
| Composite | 11/2/2007 | \$28.07 | 3883 |
| Composite | 11/2/2007 | \$28.08 | 2514 |
| Composite | 11/2/2007 | \$28.09 | 8269 |
| Composite | 11/2/2007 | \$28.10 | 18608 |
| Composite | 11/2/2007 | \$28.11 | 7912 |
| Composite | 11/2/2007 | \$28.12 | 6484 |
| Composite | 11/2/2007 | \$28.13 | 3904 |
| Composite | 11/2/2007 | \$28.14 | 2436 |
| Composite | 11/2/2007 | \$28.15 | 4800 |
| Composite | 11/2/2007 | \$28.16 | 5000 |
| Composite | 11/2/2007 | \$28.30 | 18169 |
| Composite | 11/2/2007 | \$28.31 | 3990 |
| Composite | 11/2/2007 | \$28.32 | 1393 |
| Composite | 11/2/2007 | \$28.33 | 1938 |
| Composite | 11/2/2007 | \$28.34 | 810 |
| Composite | 11/2/2007 | \$28.35 | 2700 |
| Composite | 11/2/2007 | \$28.36 | 1000 |
| Composite | 11/2/2007 | \$28.41 | 3100 |
| Composite | 11/2/2007 | \$28.43 | 100 |
| Composite | 11/2/2007 | \$28.44 | 3700 |
| Composite | 11/2/2007 | \$28.45 | 39698 |
| Composite | 11/2/2007 | \$28.46 | 800 |
| Composite | 11/2/2007 | \$28.47 | 2602 |
| Composite | 11/2/2007 | \$28.50 | 855 |
| Composite | 11/2/2007 | \$28.51 | 416 |
| Composite | 11/2/2007 | \$28.52 | 1200 |
| Composite | 11/2/2007 | \$28.53 | 1212 |
| Composite | 11/2/2007 | \$28.54 | 5794 |
| Composite | 11/2/2007 | \$28.55 | 5819 |
| Composite | 11/2/2007 | \$28.56 | 1300 |
| Composite | 11/2/2007 | \$28.57 | 1300 |
| Composite | 11/2/2007 | \$28.58 | 400 |
| Composite | 11/2/2007 | \$28.59 | 904 |
| Composite | 11/2/2007 | \$28.60 | 800 |
| Synoptic | 11/2/2007 | \$27.87 | (26) |
| Synoptic | 11/2/2007 | \$28.01 | (100) |
| Synoptic | 11/2/2007 | \$28.08 | 300 |
| Synoptic | 11/2/2007 | \$28.09 | 200 |
| Synoptic | 11/2/2007 | \$28.29 | 1000 |
| Synoptic | 11/2/2007 | \$28.38 | (500) |
| Synoptic | 11/2/2007 | \$28.42 | (100) |
| Synoptic | 11/2/2007 | \$28.57 | (212) |
| Synoptic | 11/2/2007 | \$28.59 | (300) |
| Synoptic | 11/2/2007 | \$28.71 | (300) |
| Synoptic | 11/2/2007 | \$28.77 | (116) |
| Valence | 11/2/2007 | \$28.16 | (1302) |
| Composite | 11/5/2007 | \$28.20 | 5000 |
| Composite | 11/5/2007 | \$28.21 | 500 |
| Composite | 11/5/2007 | \$28.23 | 26300 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|-----------|---------|--------|
| Composite | 11/5/2007 | \$28.24 | 2900 |
| Composite | 11/5/2007 | \$28.25 | 16500 |
| Synoptic | 11/5/2007 | \$28.24 | (100) |
| Synoptic | 11/5/2007 | \$28.26 | 1000 |
| Synoptic | 11/5/2007 | \$28.27 | (200) |
| Synoptic | 11/5/2007 | \$28.30 | (300) |
| Synoptic | 11/5/2007 | \$28.31 | (300) |
| Synoptic | 11/5/2007 | \$28.33 | (40) |
| Synoptic | 11/5/2007 | \$28.36 | (234) |
| Synoptic | 11/5/2007 | \$28.39 | (100) |
| Synoptic | 11/5/2007 | \$28.40 | 232 |
| Synoptic | 11/5/2007 | \$28.46 | (300) |
| Synoptic | 11/6/2007 | \$28.32 | 29 |
| Synoptic | 11/6/2007 | \$28.51 | (12) |
| Synoptic | 11/6/2007 | \$28.60 | (87) |
| Synoptic | 11/6/2007 | \$28.61 | (182) |
| Composite | 11/7/2007 | \$27.74 | 900 |
| Composite | 11/7/2007 | \$27.81 | 1300 |
| Composite | 11/7/2007 | \$27.83 | 1600 |
| Composite | 11/7/2007 | \$27.84 | 1056 |
| Composite | 11/7/2007 | \$27.85 | 3200 |
| Composite | 11/7/2007 | \$27.86 | 4300 |
| Composite | 11/7/2007 | \$27.87 | 1328 |
| Composite | 11/7/2007 | \$27.88 | 1972 |
| Composite | 11/7/2007 | \$27.89 | 700 |
| Composite | 11/7/2007 | \$27.90 | 200 |
| Composite | 11/7/2007 | \$27.91 | 3744 |
| Composite | 11/7/2007 | \$27.92 | 200 |
| Composite | 11/7/2007 | \$27.93 | 1400 |
| Composite | 11/7/2007 | \$27.96 | 200 |
| Composite | 11/7/2007 | \$27.97 | 500 |
| Composite | 11/7/2007 | \$27.98 | 9800 |
| Composite | 11/7/2007 | \$27.99 | 11527 |
| Composite | 11/7/2007 | \$28.00 | 56073 |
| Synoptic | 11/7/2007 | \$27.83 | 17 |
| Synoptic | 11/7/2007 | \$28.00 | 100 |
| Valence | 11/7/2007 | \$27.91 | (2000) |
| Synoptic | 11/8/2007 | \$27.63 | (235) |
| Synoptic | 11/8/2007 | \$27.65 | (300) |
| Synoptic | 11/8/2007 | \$27.68 | (100) |
| Synoptic | 11/8/2007 | \$27.80 | (200) |
| Synoptic | 11/8/2007 | \$27.81 | 17 |
| Synoptic | 11/8/2007 | \$27.81 | (300) |
| Synoptic | 11/8/2007 | \$27.85 | (100) |
| Synoptic | 11/8/2007 | \$27.88 | 46 |
| Synoptic | 11/8/2007 | \$27.89 | (100) |
| Synoptic | 11/8/2007 | \$27.93 | (100) |
| Valence | 11/8/2007 | \$27.88 | (3700) |
| Composite | 11/9/2007 | \$27.15 | 758 |
| Composite | 11/9/2007 | \$27.16 | 1342 |
| Composite | 11/9/2007 | \$27.17 | 2100 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|-----------|---------|------|
| Composite | 11/9/2007 | \$27.18 | 2800 |
| Composite | 11/9/2007 | \$27.19 | 700 |
| Composite | 11/9/2007 | \$27.20 | 1600 |
| Composite | 11/9/2007 | \$27.21 | 400 |
| Composite | 11/9/2007 | \$27.22 | 2900 |
| Composite | 11/9/2007 | \$27.23 | 2300 |
| Composite | 11/9/2007 | \$27.24 | 1900 |
| Composite | 11/9/2007 | \$27.25 | 2800 |
| Composite | 11/9/2007 | \$27.26 | 2100 |
| Composite | 11/9/2007 | \$27.27 | 3300 |
| Composite | 11/9/2007 | \$27.28 | 1954 |
| Composite | 11/9/2007 | \$27.29 | 1300 |
| Composite | 11/9/2007 | \$27.30 | 600 |
| Composite | 11/9/2007 | \$27.31 | 846 |
| Composite | 11/9/2007 | \$27.32 | 300 |
| Composite | 11/9/2007 | \$27.37 | 432 |
| Composite | 11/9/2007 | \$27.38 | 2009 |
| Composite | 11/9/2007 | \$27.39 | 2400 |
| Composite | 11/9/2007 | \$27.40 | 159 |
| Composite | 11/9/2007 | \$27.43 | 724 |
| Composite | 11/9/2007 | \$27.44 | 2781 |
| Composite | 11/9/2007 | \$27.45 | 4229 |
| Composite | 11/9/2007 | \$27.48 | 1800 |
| Composite | 11/9/2007 | \$27.49 | 1287 |
| Composite | 11/9/2007 | \$27.50 | 2264 |
| Composite | 11/9/2007 | \$27.54 | 387 |
| Composite | 11/9/2007 | \$27.55 | 4613 |
| Composite | 11/9/2007 | \$27.56 | 500 |
| Composite | 11/9/2007 | \$27.57 | 2500 |
| Composite | 11/9/2007 | \$27.58 | 1200 |
| Composite | 11/9/2007 | \$27.59 | 815 |
| Composite | 11/9/2007 | \$27.60 | 900 |
| Composite | 11/9/2007 | \$27.61 | 400 |
| Composite | 11/9/2007 | \$27.62 | 600 |
| Composite | 11/9/2007 | \$27.65 | 3663 |
| Composite | 11/9/2007 | \$27.68 | 300 |
| Composite | 11/9/2007 | \$27.69 | 900 |
| Composite | 11/9/2007 | \$27.70 | 7561 |
| Composite | 11/9/2007 | \$27.71 | 100 |
| Composite | 11/9/2007 | \$27.75 | 1900 |
| Composite | 11/9/2007 | \$27.78 | 252 |
| Composite | 11/9/2007 | \$27.79 | 466 |
| Composite | 11/9/2007 | \$27.80 | 3794 |
| Composite | 11/9/2007 | \$27.81 | 2458 |
| Composite | 11/9/2007 | \$27.82 | 1706 |
| Composite | 11/9/2007 | \$27.83 | 1200 |
| Composite | 11/9/2007 | \$27.84 | 2100 |
| Composite | 11/9/2007 | \$27.85 | 3200 |
| Composite | 11/9/2007 | \$27.88 | 500 |
| Composite | 11/9/2007 | \$27.90 | 9651 |
| Composite | 11/9/2007 | \$27.91 | 249 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|------------|---------|--------|
| Synoptic | 11/9/2007 | \$27.41 | 14 |
| Synoptic | 11/9/2007 | \$27.45 | (12) |
| Synoptic | 11/9/2007 | \$27.63 | (100) |
| Synoptic | 11/9/2007 | \$27.82 | 1200 |
| Synoptic | 11/9/2007 | \$27.89 | 600 |
| Composite | 11/12/2007 | \$27.46 | 1002 |
| Composite | 11/12/2007 | \$27.51 | 6090 |
| Synoptic | 11/12/2007 | \$27.49 | 116 |
| Synoptic | 11/12/2007 | \$27.52 | 300 |
| Synoptic | 11/12/2007 | \$27.54 | (9) |
| Synoptic | 11/12/2007 | \$27.60 | (842) |
| Synoptic | 11/12/2007 | \$27.72 | (10) |
| Synoptic | 11/12/2007 | \$27.74 | (218) |
| Synoptic | 11/12/2007 | \$27.75 | 300 |
| Synoptic | 11/12/2007 | \$27.78 | 300 |
| Synoptic | 11/12/2007 | \$27.86 | (44) |
| Composite | 11/13/2007 | \$27.15 | 3429 |
| Composite | 11/13/2007 | \$27.17 | 200 |
| Composite | 11/13/2007 | \$27.21 | 600 |
| Composite | 11/13/2007 | \$27.22 | 1171 |
| Composite | 11/13/2007 | \$27.23 | 1389 |
| Composite | 11/13/2007 | \$27.24 | 1930 |
| Composite | 11/13/2007 | \$27.25 | 7510 |
| Composite | 11/13/2007 | \$27.26 | 4162 |
| Composite | 11/13/2007 | \$27.27 | 12600 |
| Composite | 11/13/2007 | \$27.28 | 2500 |
| Composite | 11/13/2007 | \$27.29 | 2200 |
| Composite | 11/13/2007 | \$27.30 | 13305 |
| Composite | 11/13/2007 | \$27.33 | 1331 |
| Composite | 11/13/2007 | \$27.34 | 3300 |
| Composite | 11/13/2007 | \$27.35 | 773 |
| Composite | 11/13/2007 | \$27.36 | 800 |
| Composite | 11/13/2007 | \$27.37 | 4000 |
| Composite | 11/13/2007 | \$27.38 | 3800 |
| Composite | 11/13/2007 | \$27.39 | 4200 |
| Composite | 11/13/2007 | \$27.40 | 5600 |
| Composite | 11/13/2007 | \$27.41 | 11400 |
| Composite | 11/13/2007 | \$27.42 | 900 |
| Composite | 11/13/2007 | \$27.43 | 100 |
| Composite | 11/13/2007 | \$27.44 | 100 |
| Composite | 11/13/2007 | \$27.45 | 1200 |
| Composite | 11/13/2007 | \$27.46 | 600 |
| Composite | 11/13/2007 | \$27.47 | 2700 |
| Composite | 11/13/2007 | \$27.48 | 500 |
| Composite | 11/13/2007 | \$27.49 | 2600 |
| Composite | 11/13/2007 | \$27.50 | 5100 |
| Synoptic | 11/13/2007 | \$27.08 | (1000) |
| Synoptic | 11/13/2007 | \$27.32 | 57 |
| Synoptic | 11/13/2007 | \$27.39 | 206 |
| Synoptic | 11/13/2007 | \$27.40 | 300 |
| DESIM LLC | 11/14/2007 | \$27.60 | (300) |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|------------|---------|--------|
| DESIM LLC | 11/14/2007 | \$27.68 | (200) |
| DESIM LLC | 11/14/2007 | \$27.77 | (200) |
| DESIM LLC | 11/14/2007 | \$27.79 | (200) |
| Synoptic | 11/14/2007 | \$27.52 | 100 |
| Synoptic | 11/14/2007 | \$27.69 | (26) |
| Synoptic | 11/14/2007 | \$27.70 | 300 |
| Synoptic | 11/14/2007 | \$27.74 | 400 |
| Synoptic | 11/14/2007 | \$27.80 | 39 |
| Synoptic | 11/15/2007 | \$27.48 | 1000 |
| Synoptic | 11/15/2007 | \$27.55 | 200 |
| Synoptic | 11/15/2007 | \$27.59 | 300 |
| Synoptic | 11/15/2007 | \$27.61 | (200) |
| Synoptic | 11/15/2007 | \$27.71 | (1200) |
| Synoptic | 11/15/2007 | \$27.78 | (100) |
| Valence | 11/15/2007 | \$27.34 | 100 |
| Valence | 11/15/2007 | \$27.35 | 1000 |
| Valence | 11/15/2007 | \$27.36 | 100 |
| Valence | 11/15/2007 | \$27.37 | 400 |
| Valence | 11/15/2007 | \$27.38 | 800 |
| Valence | 11/15/2007 | \$27.39 | 400 |
| Valence | 11/15/2007 | \$27.40 | 500 |
| Valence | 11/15/2007 | \$27.41 | 400 |
| Valence | 11/15/2007 | \$27.43 | 300 |
| Valence | 11/15/2007 | \$27.44 | 600 |
| Valence | 11/15/2007 | \$27.45 | 2325 |
| Valence | 11/15/2007 | \$27.46 | 4100 |
| Valence | 11/15/2007 | \$27.47 | 5700 |
| Valence | 11/15/2007 | \$27.48 | 1600 |
| Valence | 11/15/2007 | \$27.49 | 1000 |
| Valence | 11/15/2007 | \$27.50 | 5700 |
| Valence | 11/15/2007 | \$27.51 | 6800 |
| Valence | 11/15/2007 | \$27.52 | 1257 |
| Valence | 11/15/2007 | \$27.53 | 9218 |
| Valence | 11/15/2007 | \$27.54 | 3200 |
| Valence | 11/15/2007 | \$27.55 | 6985 |
| Valence | 11/15/2007 | \$27.56 | 4015 |
| Valence | 11/15/2007 | \$27.57 | 3400 |
| Valence | 11/15/2007 | \$27.58 | 1500 |
| Valence | 11/15/2007 | \$27.59 | 100 |
| Valence | 11/15/2007 | \$27.60 | 6800 |
| Valence | 11/15/2007 | \$27.61 | 400 |
| Valence | 11/15/2007 | \$27.62 | 400 |
| Valence | 11/15/2007 | \$27.63 | 600 |
| Valence | 11/15/2007 | \$27.64 | 300 |
| Valence | 11/15/2007 | \$27.65 | 200 |
| Valence | 11/15/2007 | \$27.70 | 9800 |
| Valence | 11/15/2007 | \$27.71 | 700 |
| Valence | 11/15/2007 | \$27.72 | 1000 |
| Valence | 11/15/2007 | \$27.73 | 1443 |
| Valence | 11/15/2007 | \$27.74 | 1757 |
| Valence | 11/15/2007 | \$27.75 | 5100 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|-----------|------------|---------|--------|
| Valence | 11/15/2007 | \$27.80 | 2743 |
| Valence | 11/15/2007 | \$27.81 | 200 |
| Valence | 11/15/2007 | \$27.82 | 657 |
| Valence | 11/15/2007 | \$27.83 | 500 |
| Valence | 11/15/2007 | \$27.84 | 3000 |
| Valence | 11/15/2007 | \$27.85 | 2900 |
| Valence | 11/15/2007 | \$40.00 | (1000) |
| DESIM LLC | 11/16/2007 | \$27.63 | 200 |
| DESIM LLC | 11/16/2007 | \$27.65 | 200 |
| Synoptic | 11/16/2007 | \$27.30 | (100) |
| Synoptic | 11/16/2007 | \$27.34 | (100) |
| Synoptic | 11/16/2007 | \$27.46 | (1144) |
| Synoptic | 11/16/2007 | \$27.47 | 126 |
| Synoptic | 11/16/2007 | \$27.49 | 1107 |
| Synoptic | 11/16/2007 | \$27.50 | (400) |
| Synoptic | 11/16/2007 | \$27.55 | (714) |
| Synoptic | 11/16/2007 | \$27.58 | (100) |
| Synoptic | 11/16/2007 | \$27.62 | 100 |
| Synoptic | 11/16/2007 | \$27.69 | 100 |
| Valence | 11/16/2007 | \$27.37 | 81 |
| Valence | 11/16/2007 | \$27.39 | 100 |
| Valence | 11/16/2007 | \$27.45 | 1519 |
| Valence | 11/16/2007 | \$27.46 | 1900 |
| Valence | 11/16/2007 | \$27.47 | 6500 |
| Valence | 11/16/2007 | \$27.48 | 8000 |
| Valence | 11/16/2007 | \$27.49 | 9800 |
| Valence | 11/16/2007 | \$27.50 | 27100 |
| Valence | 11/16/2007 | \$27.53 | 561 |
| Valence | 11/16/2007 | \$27.54 | 600 |
| Valence | 11/16/2007 | \$27.55 | 7739 |
| Valence | 11/16/2007 | \$27.56 | 1000 |
| Valence | 11/16/2007 | \$27.57 | 4500 |
| Valence | 11/16/2007 | \$27.58 | 600 |
| Valence | 11/16/2007 | \$27.59 | 200 |
| Valence | 11/16/2007 | \$27.60 | 29800 |
| Synoptic | 11/19/2007 | \$26.84 | (688) |
| Synoptic | 11/19/2007 | \$26.85 | 100 |
| Synoptic | 11/19/2007 | \$26.94 | 333 |
| Synoptic | 11/19/2007 | \$26.97 | 394 |
| Synoptic | 11/19/2007 | \$26.98 | 246 |
| Valence | 11/19/2007 | \$26.76 | 719 |
| Valence | 11/19/2007 | \$26.77 | 16507 |
| Valence | 11/19/2007 | \$26.78 | 12904 |
| Valence | 11/19/2007 | \$26.79 | 5870 |
| Valence | 11/19/2007 | \$26.80 | 21593 |
| Valence | 11/19/2007 | \$26.81 | 200 |
| Valence | 11/19/2007 | \$26.82 | 7105 |
| Valence | 11/19/2007 | \$26.83 | 82 |
| Valence | 11/19/2007 | \$26.84 | 1000 |
| Valence | 11/19/2007 | \$26.85 | 1502 |
| Valence | 11/19/2007 | \$26.88 | 100 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|----------|------------|---------|-------|
| Valence | 11/19/2007 | \$26.89 | 200 |
| Valence | 11/19/2007 | \$26.90 | 4800 |
| Valence | 11/19/2007 | \$26.95 | 16544 |
| Valence | 11/19/2007 | \$27.00 | 10200 |
| Valence | 11/19/2007 | \$27.01 | 674 |
| Synoptic | 11/20/2007 | \$26.24 | 5 |
| Synoptic | 11/20/2007 | \$26.32 | 400 |
| Synoptic | 11/20/2007 | \$26.41 | (100) |
| Synoptic | 11/20/2007 | \$26.70 | (253) |
| Synoptic | 11/20/2007 | \$26.93 | (274) |
| Synoptic | 11/20/2007 | \$26.98 | (78) |
| Valence | 11/20/2007 | \$26.24 | 1117 |
| Valence | 11/20/2007 | \$26.26 | 500 |
| Valence | 11/20/2007 | \$26.27 | 300 |
| Valence | 11/20/2007 | \$26.28 | 200 |
| Valence | 11/20/2007 | \$26.29 | 900 |
| Valence | 11/20/2007 | \$26.30 | 1100 |
| Valence | 11/20/2007 | \$26.33 | 1600 |
| Valence | 11/20/2007 | \$26.35 | 1200 |
| Valence | 11/20/2007 | \$26.38 | 700 |
| Valence | 11/20/2007 | \$26.39 | 2300 |
| Valence | 11/20/2007 | \$26.40 | 3400 |
| Valence | 11/20/2007 | \$26.41 | 100 |
| Valence | 11/20/2007 | \$26.42 | 200 |
| Valence | 11/20/2007 | \$26.43 | 500 |
| Valence | 11/20/2007 | \$26.44 | 800 |
| Valence | 11/20/2007 | \$26.44 | (400) |
| Valence | 11/20/2007 | \$26.45 | 400 |
| Valence | 11/20/2007 | \$26.46 | 400 |
| Valence | 11/20/2007 | \$26.47 | 1100 |
| Valence | 11/20/2007 | \$26.48 | 100 |
| Valence | 11/20/2007 | \$26.49 | 200 |
| Valence | 11/20/2007 | \$26.50 | 200 |
| Valence | 11/20/2007 | \$26.53 | 100 |
| Valence | 11/20/2007 | \$26.54 | 700 |
| Valence | 11/20/2007 | \$26.56 | 500 |
| Valence | 11/20/2007 | \$26.57 | 700 |
| Valence | 11/20/2007 | \$26.59 | 200 |
| Valence | 11/20/2007 | \$26.60 | 300 |
| Valence | 11/20/2007 | \$26.64 | 900 |
| Valence | 11/20/2007 | \$26.66 | 200 |
| Valence | 11/20/2007 | \$26.67 | 400 |
| Valence | 11/20/2007 | \$26.70 | 700 |
| Valence | 11/20/2007 | \$26.71 | 300 |
| Valence | 11/20/2007 | \$26.73 | 200 |
| Valence | 11/20/2007 | \$26.76 | 300 |
| Valence | 11/20/2007 | \$26.83 | 1100 |
| Valence | 11/20/2007 | \$26.85 | 400 |
| Valence | 11/20/2007 | \$26.91 | 300 |
| Valence | 11/20/2007 | \$26.97 | 500 |
| Valence | 11/20/2007 | \$26.98 | 200 |

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

| | | | |
|---------|------------|---------|------|
| Valence | 11/20/2007 | \$26.99 | 1500 |
| Valence | 11/20/2007 | \$27.00 | 2200 |
| Valence | 11/20/2007 | \$27.03 | 400 |
| Valence | 11/20/2007 | \$27.04 | 700 |
| Valence | 11/20/2007 | \$27.05 | 300 |
| Valence | 11/20/2007 | \$27.06 | 300 |
| Valence | 11/20/2007 | \$27.09 | 397 |
| Valence | 11/20/2007 | \$27.11 | 500 |

The trading dates, transactions, exercises and assignments, and the price per share implied by the transactions, for all transactions by the Reporting Persons in options of the Issuer within the last 60 days through November 20, 2007, which were all brokered transactions, are set forth below.

| Entity | Date | Security Description | Action | Notional number of shares | Price per Contract |
|---------|------------|----------------------|--------|---------------------------|--------------------|
| | | \$35 October | | | |
| Valence | 10/19/2007 | 2007 put | Expiry | 3400 | 0 |
| | | \$40 January | | | |
| Valence | 11/15/2007 | 2010 put | Expiry | (1000) | 0 |

(d) Other than with respect to Common Shares which Valence has the right to acquire through call options, no person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares set forth above.

Clause (e) of Item 5 of Schedule 13D is not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

As of November 20, 2007, Valence maintains an open short position on 21 put option contracts based upon the value of the Common Shares. In addition to the Common Shares that it beneficially owns without reference to these contracts, Valence has long economic exposure to 2,100 Common Shares through such contracts. Valence maintains an open short position on 50 call option contracts and therefore has short economic exposure to 5,000 Common Shares through such contracts. Valence also maintains an open short position of 5,000 Common Shares. These contracts and arrangements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership in any securities that may be referenced with any person with respect to any securities of the Issuer.

As of November 20, 2007, Synoptic maintains an open short position of 342 Common Shares.

Except for the matters described herein, neither the Reporting Persons nor, to the best knowledge of any Reporting Persons, any of the persons listed in Item 2 has any contract, arrangement, understanding or relationship with any person with respect to any securities of the Issuer as of November 20, 2007.

Item 7. Material to be Filed as Exhibits

Exhibit 1 Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated October 24, 2007.

Exhibit 2

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form SC 13D/A

Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co. II, Inc., in favor of the signatories hereto, among others, dated October 24, 2007.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct.

Dated: November 21, 2007

D. E. SHAW COMPOSITE PORTFOLIOS, L.L.C.

By: D. E. SHAW & CO., L.L.C., as Managing
Member

By: /s/ Maximilian Stone
Name: Maximilian Stone
Title: Managing Director

D. E. SHAW VALENCE PORTFOLIOS, L.L.C.

By: D. E. SHAW & CO., L.P., as Managing
Member

By: /s/ Maximilian Stone
Name: Maximilian Stone
Title: Managing Director

D. E. SHAW SYNOPTIC PORTFOLIOS 2, L.L.C.

By: D. E. SHAW & CO., L.L.C., as Managing
Member

By: /s/ Maximilian Stone
Name: Maximilian Stone
Title: Managing Director

D. E. SHAW & Co., L.L.C.

By: /s/ Maximilian Stone
Name: Maximilian
Stone
Title: Managing
Director

D. E. SHAW & Co., L.P.

By: /s/ Maximilian Stone
Name: Maximilian
Stone
Title: Managing
Director

DAVID E. SHAW

By: /s/ Maximilian Stone
Name: Maximilian
Stone
Title: Attorney-in-Fact
for David E. Shaw